These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Pijpe J; van Imhoff GW; Vissink A; van der Wal JE; Kluin PM; Spijkervet FK; Kallenberg CG; Bootsma H Ann Rheum Dis; 2005 Jun; 64(6):958-60. PubMed ID: 15576414 [TBL] [Abstract][Full Text] [Related]
26. Mucosa-associated lymphoid tissue (MALT) lymphoma of the esophagus. Tsujii Y; Nishida T; Kato M; Inoue T; Yamamoto S; Hayashi Y; Akasaka T; Kondo J; Yamada T; Shinzaki S; Iijima H; Tsujii M; Takehara T Dis Esophagus; 2013 Apr; 26(3):349-50. PubMed ID: 22882544 [No Abstract] [Full Text] [Related]
27. Extraosseous plasmacytoma in the nasal cavity after rituximab therapy against pulmonary MALT lymphoma. Nakamura F; Nakamura F; Ikemura M; Fukayama M; Kurokawa M Ann Hematol; 2016 Oct; 95(10):1733-5. PubMed ID: 27435814 [No Abstract] [Full Text] [Related]
29. Cytotoxic T cell-mediated gastritis after rituximab treatment for gastric malt lymphoma. Stalika E; Kanellis G; Papalexandri A; Iskas M; Vrakidou E; Demonakou M; Anagnostopoulos A; Stamatopoulos K; Papadaki T Leuk Lymphoma; 2014 Mar; 55(3):702-5. PubMed ID: 23725385 [No Abstract] [Full Text] [Related]
30. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. Martinelli G; Laszlo D; Ferreri AJ; Pruneri G; Ponzoni M; Conconi A; Crosta C; Pedrinis E; Bertoni F; Calabrese L; Zucca E J Clin Oncol; 2005 Mar; 23(9):1979-83. PubMed ID: 15668468 [TBL] [Abstract][Full Text] [Related]
31. Possible clinical effects of macrolides on the treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma. Yatera K; Ishimatsu Y; Sakamoto N; Mukae H Int J Hematol; 2016 Feb; 103(2):251-2. PubMed ID: 26590918 [No Abstract] [Full Text] [Related]
32. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab. Ates O; Sunar V; Babacan T; Akin S; Kertmen N; Altundag K J BUON; 2015; 20(1):349. PubMed ID: 25778339 [No Abstract] [Full Text] [Related]
33. [A case of MALT lymphoma of the liver treated by RFA and Rituximab]. Hamada M; Tanaka Y; Kobayashi Y; Takeshita E; Joko K Nihon Shokakibyo Gakkai Zasshi; 2006 Jun; 103(6):655-60. PubMed ID: 16800289 [TBL] [Abstract][Full Text] [Related]
34. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Conconi A; Martinelli G; Thiéblemont C; Ferreri AJ; Devizzi L; Peccatori F; Ponzoni M; Pedrinis E; Dell'Oro S; Pruneri G; Filipazzi V; Dietrich PY; Gianni AM; Coiffier B; Cavalli F; Zucca E Blood; 2003 Oct; 102(8):2741-5. PubMed ID: 12842999 [TBL] [Abstract][Full Text] [Related]
35. Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis. Niscola P; Palumbo R; Scaramucci L; Tendas A; Cupelli L; Giovannini M; Piccioni D; Dentamaro T; Perrotti AP; de Fabritiis P Cancer Chemother Pharmacol; 2009 Mar; 63(4):759-60. PubMed ID: 18500519 [No Abstract] [Full Text] [Related]
36. Primary pulmonary lymphoma: a case of 'unresolving pneumonia'. Cherian SV; Thampy E; Mauzo SH Am J Med; 2014 Mar; 127(3):e3-4. PubMed ID: 24365165 [No Abstract] [Full Text] [Related]